Abstract
Several studies support, both in vitro and in vivo, the anti-cancer effects of cannabidiol (CBD), a transient receptor potential vanilloid 2 (TRPV2) ligand. TRPV2, often dysregulated in tumors, is associated with altered cell proliferation and aggressiveness. Endometrial cancer (EC) is historically divided in type I endometrioid EC and type II non-endometrioid EC, associated with poor prognosis. Treatment options with chemotherapy and combinations with radiation showed only limited efficacy. Since no data are reported concerning TRPV2 expression as well as CBD potential effects in EC, the aim of this study was to evaluate the expression of TRPV2 in biopsies and cell lines as well as the effects of CBD in in vitro models. Overall survival (OS), progression-free survival (PFS), cell viability, migration, and chemo-resistance have been evaluated. Results show that TRPV2 expression increased with the malignancy of the cancer tissue and correlated with shorter PFS (p = 0.0224). Moreover, in vitro TRPV2 over-expression in Ishikawa cell line increased migratory ability and response to cisplatin. CBD reduced cell viability, activating predominantly apoptosis in type I cells and autophagy in mixed type EC cells. The CBD improved chemotherapeutic drugs cytotoxic effects, enhanced by TRPV2 over-expression. Hence, TRPV2 could be considered as a marker for optimizing the therapy and CBD might be a useful therapeutic option as adjuvant therapy.
Highlights
Medical Cannabis (MC) and pure phyto-cannabinoids have been largely studied for their ability to ameliorate some of the most common and debilitating symptoms in cancer patients, like nausea, vomiting and pain [1,2].In addition to these effects, MC and THC/CBD have attracted attention as potential anti-tumoral drugs, mainly as adjuvant for current therapies in different type of cancers [3]
TRPV1 and transient receptor potential vanilloid 2 (TRPV2) were expressed in Endometrial cancer (EC) samples of both types
TRPV1 was more expressed in serous subtype (p < 0.05) while TRPV2 was more expressed in endometrioid subtype (p < 0.05) (Figure 1)
Summary
Medical Cannabis (MC) and pure phyto-cannabinoids (as tetrahydrocannabinol, THC and cannabidiol, CBD) have been largely studied for their ability to ameliorate some of the most common and debilitating symptoms in cancer patients, like nausea, vomiting and pain [1,2]. In addition to these effects, MC and THC/CBD have attracted attention as potential anti-tumoral drugs, mainly as adjuvant for current therapies in different type of cancers [3]. Cannabidiol-related ID-RMs effects have been described in cancer and are mainly based on evidences obtained in cell lines where the CBD receptors (CB1/CB2/TRPs) are not detected [20,29]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
